When Evidence Gap Becomes a Commercial Liability
The MENA evidence gap for selected portfolios is becoming a commercial liability for drugmakers that could have been prevented at the design stage.
Alaa Alyahyawi
Dr. Alaa Alyahyawi
is an independent evidence generation advisor to healthcare and life sciences organizations in Saudi Arabia, where he focuses on clinical research strategy, real-world evidence design, and research operations. He holds a PhD in Cancer and Inflammation from Queen Mary University of London, has held multiple clinical research roles in multinational pharma and a tertiary hospital, and co-founded a health-tech startup to advance early detection of chronic diseases in the MENA region.